Research programme: cancer metabolism therapeutics - Agios/Celgene

Drug Profile

Research programme: cancer metabolism therapeutics - Agios/Celgene

Alternative Names: AGI-14100; Glutaminase - Agios/Celgene; isocitrate dehydrogenase inhibitors - Agios/Celgene

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Agios Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Glutamine inhibitors; Isocitrate dehydrogenase 1 inhibitors; Isocitrate dehydrogenase 2 inhibitors; Phosphofructokinase modulators; Pyruvate kinase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Myelodysplastic syndromes
  • Research Cancer
  • No development reported Brain cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Brain-cancer in USA (PO)
  • 17 May 2016 Agios Pharmaceuticals and Celgene Corporation agree to co-develop metaboli immuno oncology therapeutics
  • 11 Dec 2013 Agios and Celgene extend their collaboration until 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top